Skip to main content
Erschienen in: Pathology & Oncology Research 1/2018

10.02.2017 | Original Article

Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients

verfasst von: Mei Jin, Zi-Wen Long, Jing Yang, Xiang Lin

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

This case-control study aims to investigate the correlations of insulin-like growth factor receptor 1 (IGF-1R) and cyclooxygenase 2 (COX-2) expressions with Ras and BRAF genetic mutations, clinicopathological features and prognosis of colorectal cancer (CRC) patients. A total of 213 CRC patients (case group) and 200 healthy individuals (control group) were selected from our hospital. Ras (K-Ras/N-Ras) and BRAF genetic mutations were detected by direct sequencing. The positive expression rates of IGF-IR and COX-2 in CRC and normal tissues were detected using immunohistochemistry. RT-qPCR and Western blotting were applied to detect the mRNA and protein expressions of IGF-IR and COX-2 in CRC tissues and normal tissues. Total mutation rate of N-Ras, BRAF and K-Ras in case group were 5.2%, 12.2% and 47.4%, respectively. The expressions of IGF-IR and COX-2 were higher in CRC tissues with Ras and BRAF mutations than in those without. CRC tissues with Ras mutation showed higher COX-2 expression than those with BRAF mutation. IGF-IR and COX-2 expressions were correlated to infiltration degree, lymphatic metastasis (in CRC tissues with and without Ras and BRAF mutations), and Dukes stages (only in CRC tissues with Ras and BRAF mutations). CRC patients with negative expressions of IGF-IR and COX-2 had significantly higher accumulative survival rate and longer mean survival duration than those with positive expressions of IGF-IR and COX-2. These findings indicate that IGF-1R and COX-2 expressions may be associated with Ras and BRAF genetic mutations, clinicopathological feature and prognosis of CRC patients.
Literatur
1.
Zurück zum Zitat Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR (2013) Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(3):93–113PubMed Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR (2013) Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(3):93–113PubMed
3.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, Group EGW (2010) Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–v77. doi:10.1093/annonc/mdq168 CrossRefPubMed Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, Group EGW (2010) Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–v77. doi:10.​1093/​annonc/​mdq168 CrossRefPubMed
6.
Zurück zum Zitat Vanamala J, Reddivari L, Radhakrishnan S, Tarver C (2010) Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p 53 signaling pathways. BMC Cancer 10:238. doi:10.1186/1471-2407-10-238 CrossRefPubMedPubMedCentral Vanamala J, Reddivari L, Radhakrishnan S, Tarver C (2010) Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p 53 signaling pathways. BMC Cancer 10:238. doi:10.​1186/​1471-2407-10-238 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, Kaneko T, Nozawa A, Adachi H, Rino Y, Masuda M, Imada T (2012) Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med 3(5):797–802. doi:10.3892/etm.2012.493 CrossRefPubMedPubMedCentral Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, Kaneko T, Nozawa A, Adachi H, Rino Y, Masuda M, Imada T (2012) Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med 3(5):797–802. doi:10.​3892/​etm.​2012.​493 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, Liu J (2012) MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 84(3):320–330. doi:10.1016/j.bcp.2012.04.017 CrossRefPubMed Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, Liu J (2012) MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 84(3):320–330. doi:10.​1016/​j.​bcp.​2012.​04.​017 CrossRefPubMed
10.
Zurück zum Zitat Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H (2010) IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 160(1):90–101. doi:10.1016/j.jss.2008.08.016 CrossRefPubMed Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H (2010) IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 160(1):90–101. doi:10.​1016/​j.​jss.​2008.​08.​016 CrossRefPubMed
14.
Zurück zum Zitat Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y, Matsubara H (2011) COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18(10):2946–2951. doi:10.1245/s10434-011-1645-z CrossRefPubMed Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y, Matsubara H (2011) COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18(10):2946–2951. doi:10.​1245/​s10434-011-1645-z CrossRefPubMed
16.
Zurück zum Zitat Lehingue Y, Urtizberea JA (1986) Tuberculosis control in Malawi. Time distribution of cessation of treatment and proposals for reorientation of the program. Bull Soc Pathol Exot Filiales 79(2):259–265PubMed Lehingue Y, Urtizberea JA (1986) Tuberculosis control in Malawi. Time distribution of cessation of treatment and proposals for reorientation of the program. Bull Soc Pathol Exot Filiales 79(2):259–265PubMed
17.
Zurück zum Zitat Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT (2012) Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 14(7):624–633CrossRefPubMedPubMedCentral Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT (2012) Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 14(7):624–633CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634. doi:10.1200/JCO.2007.14.7116 CrossRefPubMed Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634. doi:10.​1200/​JCO.​2007.​14.​7116 CrossRefPubMed
19.
Zurück zum Zitat Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 28(31):4697–4705. doi:10.1200/JCO.2009.27.4860 CrossRefPubMed Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 28(31):4697–4705. doi:10.​1200/​JCO.​2009.​27.​4860 CrossRefPubMed
20.
Zurück zum Zitat Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706–4713. doi:10.1200/JCO.2009.27.6055 CrossRefPubMed Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706–4713. doi:10.​1200/​JCO.​2009.​27.​6055 CrossRefPubMed
21.
Zurück zum Zitat Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-folfox4 treatment and ras mutations in colorectal cancer. N Engl J Med 369(11):1023–1034. doi:10.1056/NEJMoa1305275 CrossRefPubMed Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-folfox4 treatment and ras mutations in colorectal cancer. N Engl J Med 369(11):1023–1034. doi:10.​1056/​NEJMoa1305275 CrossRefPubMed
23.
Zurück zum Zitat Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) Kras and braf mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the mrc focus trial. J Clin Oncol 27(35):5931–5937. doi:10.1200/JCO.2009.22.4295 CrossRefPubMed Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) Kras and braf mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the mrc focus trial. J Clin Oncol 27(35):5931–5937. doi:10.​1200/​JCO.​2009.​22.​4295 CrossRefPubMed
24.
Zurück zum Zitat Mastroleo I (2015) Post-trial obligations in the declaration of Helsinki 2013: classification, reconstruction and interpretation. Dev World Bioeth. doi:10.1111/dewb.12099 PubMed Mastroleo I (2015) Post-trial obligations in the declaration of Helsinki 2013: classification, reconstruction and interpretation. Dev World Bioeth. doi:10.​1111/​dewb.​12099 PubMed
25.
26.
Zurück zum Zitat Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjanen K, El-Faitori O, Latto M, Collan Y, Pyrhonen S (2013) High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 33(8):3137–3143PubMed Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjanen K, El-Faitori O, Latto M, Collan Y, Pyrhonen S (2013) High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 33(8):3137–3143PubMed
27.
Zurück zum Zitat Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM (2015) Irs2 copy number gain, kras and braf mutation status as predictive biomarkers for response to the igf-1r/ir inhibitor bms-754807 in colorectal cancer cell lines. Mol Cancer Ther 14(2):620–630. doi:10.1158/1535-7163.MCT-14-0794-T CrossRefPubMed Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM (2015) Irs2 copy number gain, kras and braf mutation status as predictive biomarkers for response to the igf-1r/ir inhibitor bms-754807 in colorectal cancer cell lines. Mol Cancer Ther 14(2):620–630. doi:10.​1158/​1535-7163.​MCT-14-0794-T CrossRefPubMed
28.
Zurück zum Zitat Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2006) Coexpression of the igf-ir, egfr and her-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–335PubMed Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2006) Coexpression of the igf-ir, egfr and her-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–335PubMed
29.
Zurück zum Zitat Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM (2012) Braf mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon rectum 55(2):128–133. doi:10.1097/DCR.0b013e31823c08b3 Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM (2012) Braf mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon rectum 55(2):128–133. doi:10.​1097/​DCR.​0b013e31823c08b3​
30.
Zurück zum Zitat Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM (2007) Regulation of cyclooxygenase-2 (cox-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-i receptor (igf-ir) system. Cancer Lett 258(2):291–300. doi:10.1016/j.canlet.2007.09.009 CrossRefPubMedPubMedCentral Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM (2007) Regulation of cyclooxygenase-2 (cox-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-i receptor (igf-ir) system. Cancer Lett 258(2):291–300. doi:10.​1016/​j.​canlet.​2007.​09.​009 CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wu CM, Li TM, Hsu SF, Su YC, Kao ST, Fong YC, Tang CH (2011) IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells. J Cell Physiol 226(12):3270–3277. doi:10.1002/jcp.22688 CrossRefPubMed Wu CM, Li TM, Hsu SF, Su YC, Kao ST, Fong YC, Tang CH (2011) IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells. J Cell Physiol 226(12):3270–3277. doi:10.​1002/​jcp.​22688 CrossRefPubMed
32.
Zurück zum Zitat Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, Hsu CJ, Jeng LB, Chen CY, Tang CH (2010) Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 9:43. doi:10.1186/1476-4598-9-43 CrossRefPubMedPubMedCentral Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, Hsu CJ, Jeng LB, Chen CY, Tang CH (2010) Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 9:43. doi:10.​1186/​1476-4598-9-43 CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Lee Y C YCN and, Hsu T (2013) Abstract 1146: Stk4 downregulation promotes tumor invasion/migration and is associated with poor prognosis in human colon cancer. Cancer Res 73 (8 Supplement): 1146–1146 Lee Y C YCN and, Hsu T (2013) Abstract 1146: Stk4 downregulation promotes tumor invasion/migration and is associated with poor prognosis in human colon cancer. Cancer Res 73 (8 Supplement): 1146–1146
36.
Zurück zum Zitat Zare Mirzaei A, Abdorrazaghi F, Lotfi M, Kazemi Nejad Band Shayanfar N (2015) Prognostic value of lymph node ratio in comparison to lymph node metastases in stage iii colon cancer. Iran J Pathol 10(2):127–135 Zare Mirzaei A, Abdorrazaghi F, Lotfi M, Kazemi Nejad Band Shayanfar N (2015) Prognostic value of lymph node ratio in comparison to lymph node metastases in stage iii colon cancer. Iran J Pathol 10(2):127–135
Metadaten
Titel
Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients
verfasst von
Mei Jin
Zi-Wen Long
Jing Yang
Xiang Lin
Publikationsdatum
10.02.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0195-5

Weitere Artikel der Ausgabe 1/2018

Pathology & Oncology Research 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.